MPH Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicure Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.00 |
| 52 Week High | CA$1.80 |
| 52 Week Low | CA$0.99 |
| Beta | 1.01 |
| 1 Month Change | 1.01% |
| 3 Month Change | -23.08% |
| 1 Year Change | -1.96% |
| 3 Year Change | -16.67% |
| 5 Year Change | -81.48% |
| Change since IPO | -90.74% |
Recent News & Updates
Estimating The Fair Value Of Medicure Inc. (CVE:MPH)
May 14
Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel
Mar 08Recent updates
Estimating The Fair Value Of Medicure Inc. (CVE:MPH)
May 14Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) Tunnel
Mar 08We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With Ease
Aug 28Medicure's (CVE:MPH) Earnings Are Weaker Than They Seem
Nov 30Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More Closely
Jun 15Shareholder Returns
| MPH | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -5.7% | -2.5% | 1.2% |
| 1Y | -2.0% | -34.5% | 11.8% |
Return vs Industry: MPH exceeded the Canadian Biotechs industry which returned -34.5% over the past year.
Return vs Market: MPH underperformed the Canadian Market which returned 11.8% over the past year.
Price Volatility
| MPH volatility | |
|---|---|
| MPH Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 17.9% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: MPH's share price has been volatile over the past 3 months.
Volatility Over Time: MPH's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Albert Friesen | www.medicure.com |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia.
Medicure Inc. Fundamentals Summary
| MPH fundamental statistics | |
|---|---|
| Market cap | CA$10.54m |
| Earnings (TTM) | -CA$922.00k |
| Revenue (TTM) | CA$21.69m |
0.5x
P/S Ratio-11.3x
P/E RatioIs MPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MPH income statement (TTM) | |
|---|---|
| Revenue | CA$21.69m |
| Cost of Revenue | CA$7.71m |
| Gross Profit | CA$13.99m |
| Other Expenses | CA$14.91m |
| Earnings | -CA$922.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.088 |
| Gross Margin | 64.48% |
| Net Profit Margin | -4.25% |
| Debt/Equity Ratio | 0% |
How did MPH perform over the long term?
See historical performance and comparison